SARS-CoV-2 血清学免疫应答在外源性免疫抑制患者中的表现。
SARS-CoV-2 Serologic Immune Response in Exogenously Immunosuppressed Patients.
机构信息
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Pathology, University of Pittsburgh , Pittsburgh , PA, USA.
出版信息
J Appl Lab Med. 2021 Mar 1;6(2):486-490. doi: 10.1093/jalm/jfaa232.
BACKGROUND
While it is presumed that immunosuppressed patients, such as solid organ transplant recipients on immunosuppression, are at greater risk from SARS-CoV-2 infection than the general population, the antibody response to infection in this patient population has not been studied.
METHODS
In this report, we follow the anti-SARS-CoV-2 antibody levels in patients with COVID-19 who are undergoing exogenous immunosuppression. Specifically, we studied the antibody response of 3 solid organ transplant recipient patients, 3 patients who take daily inhaled fluticasone, and a patient on etanercept and daily inhaled fluticasone, and compared them to 5 patients not on exogenous immunosuppression.
RESULTS
We found that the solid organ transplant patients on full immunosuppression are at risk of having a delayed antibody response and poor outcome. We did not find evidence that inhaled steroids or etanercept predispose patients to delayed immune response to SARS-CoV-2.
CONCLUSION
The data presented here suggest that solid organ transplant recipients may be good candidates for early targeted intervention against SARS-CoV-2.
背景
虽然人们认为免疫抑制患者（如接受免疫抑制治疗的实体器官移植受者）感染 SARS-CoV-2 的风险高于普通人群，但尚未研究该患者人群的感染后抗体反应。
方法
在本报告中，我们跟踪了正在接受外源性免疫抑制治疗的 COVID-19 患者的抗 SARS-CoV-2 抗体水平。具体来说，我们研究了 3 名实体器官移植受者患者、3 名每日吸入氟替卡松的患者和 1 名接受依那西普和每日吸入氟替卡松治疗的患者的抗体反应，并将其与 5 名未接受外源性免疫抑制的患者进行了比较。
结果
我们发现，接受充分免疫抑制的实体器官移植患者存在抗体反应延迟和预后不良的风险。我们没有发现吸入性类固醇或依那西普使患者易发生 SARS-CoV-2 免疫反应延迟的证据。
结论
这里提供的数据表明，实体器官移植受者可能是针对 SARS-CoV-2 进行早期靶向干预的良好候选者。
Zotero 插件